Pharmacology and Therapeutic Features of COVID - 19 Infection in Hodeidah, Yemen

M. Al-Kamarany, Mohammed AL Madani, Hussien Kadi, Salah Musfer, Zain Alabdin AL Sharma, Rashad Al Salhi, Nabil Albasir
{"title":"Pharmacology and Therapeutic Features of COVID - 19 Infection in Hodeidah, Yemen","authors":"M. Al-Kamarany, Mohammed AL Madani, Hussien Kadi, Salah Musfer, Zain Alabdin AL Sharma, Rashad Al Salhi, Nabil Albasir","doi":"10.9734/jamps/2024/v26i5683","DOIUrl":null,"url":null,"abstract":"Background: The symptoms and signs of coronavirus diseases 2019 (COVID-19) present at illness onset vary, but over the course of the disease, most persons with COVID-19 will experience the following: fever , cough, fatigue, anorexia, shortness of breath, hypoxia, sputum production, and myalgia . During the first year (2020), there was no effective cure for COVID-19 infection and the most common treatment for patients was supportive therapy. Ministry of Public Health and Population in Yemen presented national guideline that is extracted from other countries and World Health Organization (WHO).\nObjective: Therefore, in this research, we discuss the pharmacological and therapeutic approaches for management of COVID-19 during its early period of rampage, using availability of medicines in Yemeni local pharmaceutical marketing. On the other hand, the efficacy of therapeutic  was monitored.\nMethodology: 505 patients with COVID-19 from Hodeidah showed that respiratory infection illness can range from mild to critical. Mild to moderate was 386 case (78.93 %) , severe  cases (dyspnea, hypoxia, or  lung involvement on imaging) was 73 cases (15.13 %) and  critical cases (respiratory failure, shock, or multiorgan system dysfunction) was 28  cases (5.93 %). The major criteria for cases admission namely clinical examination, case definition, clinical investigation, radiological finding, hematological finding , and molecular biology assay namely real – time - polymerase chain reaction (RT- PCR).  The pharmacological and therapeutic properties of supportive therapy of COVID - 19 included \" antipyretic agent , analgesic agent, glucocortocoid (dexamethasone),  anticoagulant agent (enoxaparin) , bronchodilator agent (sulbtamol), anti-cough (acetylcysteine), antibiotics  broad spectrum to treat the secondary infection namely azithromycin , ceftriaxone , piperacillin and tazobactam , vancomycine , meropenam , and moxifloxacine). In addition, oxygen therapy is the major treatment that used in treatment of severe and critical cases. Also , vitamins (C and D3) and mineral namely zinc were pecribed  and proton pump inhibitor (PPI) (pantaprazol) , anti-emetic (ondansetron). Fluid therapy namely ringer lactate or normal saline are used in management of COVID – 19.\nResults: The results showed that the age of the patients included in this study between 3- 92 years with 1.5 : 2.0 male: female.  49 patients were admitted in COVID – 19 isolation department of CTMID. 25/49 cases (54.34% ) were recovered with national guideline ,  the average of  RR  pre - treatment was 30 ± 5 breath / minute and reduced to  23 ± 2 breath / minute post – treatment with significantly statistically different (p < 0.05) . On the other hand, the clinical symptoms namely difficult in breathing, co[a]ugh ,  fever , and headache reduced to absent absolutely (100 %) .   In addition, the results showed that the average of WBC pre - treatment was 20 ± 4 (×10 9/L) and reduced to 7 ± 2 (×10 9/L) post – treatment with significantly statistically different (p < 0.05). Also, lymphocytes decreased with COVID -19 infection to 2 % with average (10±5%) and improved post - treatment to 20 %.  In addition, neutrophil increased to 95 % with average (80±15%) and improved to 70 % post-treatment. the average of WBC pre - treatment was 20 ± 4 (×10 9/L) and reduced to 7 ± 2 (×10 9/L) post-treatment with significantly statistically different (p < 0.05). The outcome finding of management that 386 cases (76.43 %) of mild and 54 cases (11.04 %) of severe were recovered at home, 19 cases (3.88 %) of severe and 6 cases (1.22 %) of critical were recovered at isolation center. On the other hand, 1 case of severe and 21 cases of critical COVID [were] died.\nConclusion: In spite of lack of specific antiviral drugs, the approach of pharmacology and therapeutics had good impact at level of mild to moderate cases, [and severe case] while severe and crititical cases needs to develop at level critical case] more intensive care (ICU) including mechanical venitlation procedure.","PeriodicalId":14903,"journal":{"name":"Journal of Advances in Medical and Pharmaceutical Sciences","volume":" 48","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Advances in Medical and Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/jamps/2024/v26i5683","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The symptoms and signs of coronavirus diseases 2019 (COVID-19) present at illness onset vary, but over the course of the disease, most persons with COVID-19 will experience the following: fever , cough, fatigue, anorexia, shortness of breath, hypoxia, sputum production, and myalgia . During the first year (2020), there was no effective cure for COVID-19 infection and the most common treatment for patients was supportive therapy. Ministry of Public Health and Population in Yemen presented national guideline that is extracted from other countries and World Health Organization (WHO). Objective: Therefore, in this research, we discuss the pharmacological and therapeutic approaches for management of COVID-19 during its early period of rampage, using availability of medicines in Yemeni local pharmaceutical marketing. On the other hand, the efficacy of therapeutic  was monitored. Methodology: 505 patients with COVID-19 from Hodeidah showed that respiratory infection illness can range from mild to critical. Mild to moderate was 386 case (78.93 %) , severe  cases (dyspnea, hypoxia, or  lung involvement on imaging) was 73 cases (15.13 %) and  critical cases (respiratory failure, shock, or multiorgan system dysfunction) was 28  cases (5.93 %). The major criteria for cases admission namely clinical examination, case definition, clinical investigation, radiological finding, hematological finding , and molecular biology assay namely real – time - polymerase chain reaction (RT- PCR).  The pharmacological and therapeutic properties of supportive therapy of COVID - 19 included " antipyretic agent , analgesic agent, glucocortocoid (dexamethasone),  anticoagulant agent (enoxaparin) , bronchodilator agent (sulbtamol), anti-cough (acetylcysteine), antibiotics  broad spectrum to treat the secondary infection namely azithromycin , ceftriaxone , piperacillin and tazobactam , vancomycine , meropenam , and moxifloxacine). In addition, oxygen therapy is the major treatment that used in treatment of severe and critical cases. Also , vitamins (C and D3) and mineral namely zinc were pecribed  and proton pump inhibitor (PPI) (pantaprazol) , anti-emetic (ondansetron). Fluid therapy namely ringer lactate or normal saline are used in management of COVID – 19. Results: The results showed that the age of the patients included in this study between 3- 92 years with 1.5 : 2.0 male: female.  49 patients were admitted in COVID – 19 isolation department of CTMID. 25/49 cases (54.34% ) were recovered with national guideline ,  the average of  RR  pre - treatment was 30 ± 5 breath / minute and reduced to  23 ± 2 breath / minute post – treatment with significantly statistically different (p < 0.05) . On the other hand, the clinical symptoms namely difficult in breathing, co[a]ugh ,  fever , and headache reduced to absent absolutely (100 %) .   In addition, the results showed that the average of WBC pre - treatment was 20 ± 4 (×10 9/L) and reduced to 7 ± 2 (×10 9/L) post – treatment with significantly statistically different (p < 0.05). Also, lymphocytes decreased with COVID -19 infection to 2 % with average (10±5%) and improved post - treatment to 20 %.  In addition, neutrophil increased to 95 % with average (80±15%) and improved to 70 % post-treatment. the average of WBC pre - treatment was 20 ± 4 (×10 9/L) and reduced to 7 ± 2 (×10 9/L) post-treatment with significantly statistically different (p < 0.05). The outcome finding of management that 386 cases (76.43 %) of mild and 54 cases (11.04 %) of severe were recovered at home, 19 cases (3.88 %) of severe and 6 cases (1.22 %) of critical were recovered at isolation center. On the other hand, 1 case of severe and 21 cases of critical COVID [were] died. Conclusion: In spite of lack of specific antiviral drugs, the approach of pharmacology and therapeutics had good impact at level of mild to moderate cases, [and severe case] while severe and crititical cases needs to develop at level critical case] more intensive care (ICU) including mechanical venitlation procedure.
也门荷台达 COVID - 19 感染的药理和治疗特点
背景:冠状病毒病 2019(COVID-19)发病时的症状和体征各不相同,但在病程中,大多数 COVID-19 感染者会出现以下症状:发热、咳嗽、乏力、厌食、气短、缺氧、痰液分泌和肌痛。在第一年(2020 年),COVID-19 感染尚无有效的治愈方法,患者最常见的治疗方法是支持疗法。也门公共卫生和人口部提出了从其他国家和世界卫生组织(WHO)借鉴的国家指导方针:因此,在本研究中,我们利用也门当地药品市场的药品供应情况,讨论了在 COVID-19 肆虐的早期对其进行治疗的药物和治疗方法。方法:荷台达的 505 名 COVID-19 患者表明,呼吸道感染疾病从轻度到重度不等。轻中度病例为 386 例(78.93%),重度病例(呼吸困难、缺氧或影像学检查肺部受累)为 73 例(15.13%),危重病例(呼吸衰竭、休克或多器官系统功能障碍)为 28 例(5.93%)。病例入院的主要标准是临床检查、病例定义、临床调查、放射学发现、血液学发现和分子生物学检测,即实时聚合酶链反应(RT- PCR)。 COVID - 19 支持疗法的药理和治疗特性包括 "解热剂、镇痛剂、糖皮质激素(地塞米松)、抗凝剂(依诺肝素)、支气管扩张剂(舒喘宁)、止咳药(乙酰半胱氨酸)、治疗继发感染的广谱抗生素(阿奇霉素、头孢曲松、哌拉西林和他唑巴坦、万古霉素、美罗培南和莫西沙星)。此外,氧疗是治疗重症和危重病例的主要方法。此外,还使用了维生素(C 和 D3)和矿物质锌,以及质子泵抑制剂(PPI)(泮托拉唑)和止吐药(昂丹司琼)。在治疗 COVID - 19 时使用了液体疗法,即乳酸林格氏液或生理盐水:结果显示,参与本研究的患者年龄在 3-92 岁之间,男女比例为 1.5:2.0。 CTMID 的 COVID - 19 隔离科收治了 49 名患者。其中 25/49 例(54.34%)按照国家指南康复,治疗前平均呼吸频率为 30 ± 5 次/分钟,治疗后平均呼吸频率降至 23 ± 2 次/分钟,差异显著(P < 0.05)。另一方面,呼吸困难、咳嗽、发热和头痛等临床症状完全消失(100%)。 此外,结果显示,治疗前白细胞平均值为 20 ± 4(×10 9/L),治疗后降至 7 ± 2(×10 9/L),差异有显著统计学意义(P < 0.05)。此外,淋巴细胞在感染 COVID -19 后下降至 2%,平均为(10±5%),治疗后提高至 20%。 治疗前白细胞平均为 20 ± 4(×10 9/L),治疗后降至 7 ± 2(×10 9/L),差异显著(P < 0.05)。治疗结果显示,386 例(76.43%)轻度患者和 54 例(11.04%)重度患者在家中康复,19 例(3.88%)重度患者和 6 例(1.22%)危重患者在隔离中心康复。另一方面,有 1 例重症和 21 例危重 COVID 患者死亡:结论:尽管缺乏特异性抗病毒药物,但药理学和治疗学方法对轻中度病例[和重度病例]有很好的疗效,而重度和危重病例则需要发展为危重病例],需要更多的重症监护(ICU),包括机械静脉通路手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信